Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Valproate in ALS
NCT00136110Phase 3Completed
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Sodium Valproate with Placebo (2 arms). Primary endpoint: Survival. Started Apr 2005; status: completed.
02
Drugs
valproic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00136110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136110.